In the dynamic field of pharmaceutical research and development, securing high-quality raw materials and advanced intermediates is paramount. For those focused on oncology, particularly prostate cancer therapies, ODM-201 (CAS: 1297538-32-9) represents a significant advancement. As a leading manufacturer and supplier of pharmaceutical intermediates in China, we pride ourselves on providing compounds that meet stringent quality standards, empowering scientific innovation worldwide.

ODM-201 is a cutting-edge androgen receptor (AR) inhibitor that has demonstrated exceptional promise in tackling castration-resistant prostate cancer (CRPC). Its unique ability to act as a potent antagonist against AR mutations that confer resistance to existing treatments, coupled with its favorable safety profile characterized by minimal brain penetrance, makes it a critical component in the development of next-generation cancer therapies. Researchers and formulators are increasingly seeking reliable sources for this compound.

Our company specializes in the synthesis and supply of complex pharmaceutical intermediates. We understand the critical nature of purity, consistency, and timely delivery for our clients. When you choose us as your ODM-201 supplier, you are partnering with a facility that adheres to rigorous quality control measures throughout the entire manufacturing process. This ensures that the ODM-201 you receive is of the highest caliber, suitable for the most demanding research and development applications.

We are dedicated to supporting the global scientific community by making advanced intermediates like ODM-201 accessible. Whether you are conducting preclinical studies, developing new formulations, or scaling up production, our capabilities as a manufacturer in China allow us to offer competitive pricing and a stable supply chain. For procurement managers and research scientists looking to buy ODM-201, we invite you to inquire about our product specifications, pricing, and sample availability. Partner with us for your critical intermediate needs.